| Eva De Smedt |
Epigenetic reprogramming of malignant plasma cells: the therapeutic potential of RASSF proteins and G9a/GLP targeting in Multiple Myeloma. |
2021 |
Elke De Bruyne
Karin Vanderkerken
|
| Christelle Orlando |
Novel insights in inherited antithrombin deficiency: from laboratory diagnosis to clinical presentation. |
2021 |
Kristin Jochmans |
| Anke Maes |
Exploring the therapeutic potential of targeting mitotic exit in combination with standard of care agents in high grade B cell malignancies
|
2019 |
Elke De Bruyne
Karin Vanderkerken
|
| Sylvia Faict |
Exosomal communication in Multiple Myeloma: Friend or Foe?” |
2019 |
Eline Menu
Karin Vanderkerken
Rik Schots |
| Nathan De Beule |
Bone marrow-induced survival: identifying novel targets in multiple myeloma
|
2018 |
Karin Vanderkerken
Eline Menu
Els Van Valckenborgh
Rik Schots |
| Mérédis Favreau |
Immune therapy in multiple myeloma: can iNKT cells be targeted? |
2017 |
Eline Menu
Karin Vanderkerken
Dirk Elewaut
Koen Venken |
| Susanne Lub |
The role of E3 ubiquitin ligases with a focus on the inhibitor of apoptosis proteins (IAPs) and the anaphase promoting complex/cyclosome (APC/C) in multiple myeloma |
2016 |
Karin Vanderkerken
Els Van Valckenborgh
|
| Liesbeth Bieghs |
The IGF system in multiple myeloma: exploring diagnostic and therapeutic potential |
2016 |
Karin Vanderkerken
Elke De Bruyne
|
| Kim De Veirman |
The role of bone marrow derived bystander cells in the development of multiple myeloma |
2016 |
Karin Vanderkerken
Els Van Valckenborgh
Ivan Van Riet
Eline Menu
|
| Jinheng Wang |
Exosomal communication in the bone marrow microenvironment: a significant player in multiple myeloma progression |
2016 |
Eline Menu
Karin Vanderkerken
|
| Ken Maes |
The therapeutic and prognostic potential of epigenetic modulating agents in multiple myeloma |
2015 |
Karin Vanderkerken
Elke De Bruyne
|
